$AMBS News - Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID

- Latest preclinical data in the peer-reviewed journal \'Movement Disorders\' support previous nonclinical and clinical findings that eltoprazine is effective against Parkinson\'s Disease L-dopa induced dyskinesia (PD-LID)

- Eltoprazine treatment attenuates the development and expression of PD-LID by regulating neurochemical circuitry involved in motor control, but does not compromise the efficacy of levodopa therapy

- Data further support the design and dose selection of the ongoing Phase 2b clinical study



SAN FRANCISCO and GENEVA, - (http://www.financialnewsmedia.com News Alert) - Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced the publication of preclinical model data demonstrating that eltoprazine prevents L-dopa induced dyskinesias. The paper entitled, \"Eltoprazine Prevents Dyskinesias by Reducing Striatal Glutamate and Direct Pathway Neuron Activity,\" from groups including the National Institute of Neuroscience in Italy, has been published in Movement Disorders, a journal of the International Parkinson and Movement Disorder Society (MDS).



Eltoprazine is a small molecule 5HT1A/1B partial agonist in Phase 2b clinical development for the treatment of Parkinson\'s disease levodopa-induced dyskinesia (PD-LID). PD-LID is an abnormal involuntary, movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson\'s disease. PD-LID occurs in approximately 60-80% of Parkinson\'s disease (PD) patients and is one of the most difficult problems facing people with the disease. This dyskinesia can be severely disabling and impact quality of life by prohibiting the ability to perform routine daily functions.



\"I am very excited by these new results, as they not only confirm the anti PD-LID activity of eltoprazine in another laboratory, but the authors also provide important evidence concerning the neurochemical mechanisms and pathways underlying eltoprazine\'s positive effects in PD-LID,\" stated David A. Lowe, Ph.D., member of the Board of Amarantus BioScience Holdings, Inc. \"Additionally this study further validates the Phase 2a clinical data published earlier this year in the journal BRAIN showing that eltoprazine...